Observing visual impairment in stroke patients
The Oslo Study of Visual Impairment After Stroke (StrokeVIS)
This study looks at how common vision problems are in stroke patients right after their stroke and three months later, comparing those who received a special treatment to those who didn't.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT05809973 on ClinicalTrials.gov |
What this trial studies
This longitudinal observational study focuses on patients admitted with acute ischemic stroke at the Regional Stroke Unit at Oslo University Hospital. It aims to determine the prevalence of visual impairment in these patients during the acute phase and after three months, comparing those treated with endovascular therapy (EVT) to those who are not. The study will utilize the Vision Screening Assessment (VISA) tool to evaluate visual impairment and assess its sensitivity and specificity. A total of 120 patients will be included based on specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have experienced an acute ischemic stroke with a National Institute of Health Stroke Scale (NIHSS) score of less than 20.
Not a fit: Patients with more severe neurological deficits or those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding and management of visual impairment in stroke patients, leading to better rehabilitation strategies.
How similar studies have performed: While there is limited data on similar observational studies specifically focusing on visual impairment post-stroke, the approach of using the VISA tool has shown promise in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Acute ischemic stroke and NIHSS \< 20 2. Age ≥18 years. 3. Written informed consent of the patient or oral informed consent witnessed by a doctor. Exclusion criteria: 1. NIHSS \< 20 2. No willingness and ability of the patient to participate in all baseline and follow-up examinations.
Where this trial is running
Oslo
- Oslo University Hospital — Oslo, Norway (Recruiting)
Study contacts
- Study coordinator: Anne Hege Aamodt, MD, PhD
- Email: a.h.aamodt@medisin.uio.no
- Phone: +4791502770
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.